Subject to Inquiry

Subject to Inquiry

THE LATEST ON GOVERNMENT INQUIRIES AND ENFORCEMENT ACTIONS

Government Investigations and White Collar Litigation Group

Clint Narver

Photo of Clint Narver Clint, a former federal prosecutor, is a member of the firm’s nationally ranked Government Investigations and White Collar Litigation Department. An experienced litigator, Clint represents companies and individuals in high-stakes criminal and civil litigation, government and internal investigations, and complex regulatory proceedings. Clint also develops corporate compliance programs and strategically advises clients on a broad range of U.S. Food and Drug Administration (FDA) legal, regulatory, and policy issues.

Subscribe to all posts by Clint Narver

Order Limiting Strict Liability Has Implications on FDCA Enforcement for Companies, Individuals

By Clint Narver, Eric Olshan, Mindy Sauter and James Hornsby on Enforcement and Prosecution Policy and Trends, Fraud, Deception and False Claims
On May 9, 2025, President Trump signed an Executive Order titled “Fighting Overcriminalization in Federal Regulations.” The Order seeks to reduce the regulatory burden on Americans and prevent individuals from being criminally penalized for unknowingly violating complex regulations.  In pursuit of these goals, the Order sets forth a policy “generally disfavor[ing]” strict liability crimes.  Agencies… Continue Reading

Healthcare Fraud Enforcement in a Second Trump Administration: Trends, Priorities, and Implications

By Mindy Sauter, Clint Narver, Michael Elliott, Garen S. Marshall, Justin Givens, Michael J. Podberesky and Rhea Shahane on Fraud, Deception and False Claims
On May 12, 2025, the United States Department of Justice’s (“DOJ”) Criminal Division released a major policy memorandum outlining its enforcement priorities for the upcoming year. Unsurprisingly, the number one priority for the Division was investigating and prosecuting white-collar crimes related to waste, fraud, and abuse—and particularly healthcare fraud. This emphasis on prosecuting healthcare fraud… Continue Reading

FDA to Expand Unannounced Inspections of Foreign Facilities — Manufacturers, Research Firms Should Prepare

By Clint Narver, Mindy Sauter, Michael F. Easley, Jr. and Rhea Shahane on Compliance
On May 6, 2025, the U.S. Food and Drug Administration (FDA) announced a plan to expand its use of unannounced inspections of foreign manufacturing facilities that produce foods, essential medicines and other medical products intended for American consumers and patients. The FDA stated that this new inspection strategy will ensure that foreign manufacturers receive the… Continue Reading

We use cookies to enhance your experience of our website. By continuing to use this website, you agree to the use of these cookies. For more information and to learn how you can change your cookie settings, please see our policy.

Agree